Literature DB >> 3980669

Differences in metabolic properties among cortisol, prednisolone, and dexamethasone in liver and renal diseases: accelerated metabolism of dexamethasone in renal failure.

S Kawai, Y Ichikawa, M Homma.   

Abstract

Since previous reports concerning the altered metabolism of various glucocorticoids in liver or renal diseases were inconsistent, this study was undertaken to reexamine the metabolism of cortisol, prednisolone, and dexamethasone in patients with these diseases. One milligram each of these glucocorticoids was given iv simultaneously to patients with chronic liver disease, patients with chronic renal failure, and normal subjects after 1 mg betamethasone was administered on the previous night to suppress endogenous cortisol secretion. Plasma steroid levels in periodically collected blood samples were assayed by respective RIA after separation by paper chromatography. Prolongation of the t1/2 of cortisol was found in both patients with liver disease and those with renal failure, and prolonged t1/2 and reduced MCR of prednisolone were found in renal failure but not in liver disease. In contrast, while prolonged t1/2 and reduced MCR of dexamethasone were found in liver disease, shortened t1/2 and increased MCR were found in renal failure. These results suggest that different glucocorticoids are metabolized differently in patients with liver disease and those with renal failure, and that these differences may be important when these agents are used for therapeutic purposes or for study of hypothalamic-pituitary-adrenocortical function in patients with liver and renal diseases.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3980669     DOI: 10.1210/jcem-60-5-848

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

Review 1.  Clinical Relevance of Steroid Use in Neuro-Oncology.

Authors:  K Ina Ly; Patrick Y Wen
Journal:  Curr Neurol Neurosci Rep       Date:  2017-01       Impact factor: 5.081

2.  Pitfalls of pharmacokinetic dosage guidelines in renal insufficiency.

Authors:  K Turnheim
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation.

Authors:  Troels K Bergmann; Katherine A Barraclough; Katie J Lee; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2012-11       Impact factor: 6.447

Review 4.  Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.

Authors:  David Czock; Frieder Keller; Franz Maximilian Rasche; Ulla Häussler
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

5.  Cortisol release from adipose tissue by 11beta-hydroxysteroid dehydrogenase type 1 in humans.

Authors:  Roland H Stimson; Jonas Andersson; Ruth Andrew; Doris N Redhead; Fredrik Karpe; Peter C Hayes; Tommy Olsson; Brian R Walker
Journal:  Diabetes       Date:  2008-10-13       Impact factor: 9.461

Review 6.  Clinical pharmacokinetic considerations in the treatment of increased intracranial pressure.

Authors:  G Heinemeyer
Journal:  Clin Pharmacokinet       Date:  1987-07       Impact factor: 6.447

Review 7.  Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update.

Authors:  D J Morgan; A J McLean
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

Review 8.  A Rationale for Age-Adapted Immunosuppression in Organ Transplantation.

Authors:  Felix Krenzien; Abdallah ElKhal; Markus Quante; Hector Rodriguez Cetina Biefer; Uehara Hirofumi; Steven Gabardi; Stefan G Tullius
Journal:  Transplantation       Date:  2015-11       Impact factor: 4.939

9.  Decreased maximal cortisol secretion rate in patients with cirrhosis: Relation to disease severity.

Authors:  Christina M Lovato; Thierry Thévenot; Sophie Borot; Vincent Di Martino; Clifford R Qualls; Frank K Urban; Richard I Dorin
Journal:  JHEP Rep       Date:  2021-03-19

10.  Glucocorticoid activation by 11β-hydroxysteroid dehydrogenase enzymes in relation to inflammation and glycaemic control in chronic kidney disease: A cross-sectional study.

Authors:  Michael S Sagmeister; Angela E Taylor; Anthony Fenton; Nadezhda A Wall; Dimitrios Chanouzas; Peter G Nightingale; Charles J Ferro; Wiebke Arlt; Paul Cockwell; Rowan S Hardy; Lorraine Harper
Journal:  Clin Endocrinol (Oxf)       Date:  2018-11-15       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.